Zacks: Brokerages Anticipate Magenta Therapeutics Inc (MGTA) to Announce -$0.46 Earnings Per Share
Wall Street analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce earnings per share (EPS) of ($0.46) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Magenta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.42). The business is scheduled to announce its next quarterly earnings report on Thursday, November 8th.
On average, analysts expect that Magenta Therapeutics will report full year earnings of ($3.06) per share for the current year, with EPS estimates ranging from ($3.15) to ($2.96). For the next financial year, analysts expect that the firm will post earnings of ($1.82) per share, with EPS estimates ranging from ($2.35) to ($1.02). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Magenta Therapeutics.
Magenta Therapeutics (NASDAQ:MGTA) last issued its earnings results on Thursday, August 9th. The company reported ($3.13) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($2.03).
A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp purchased a new position in Magenta Therapeutics in the second quarter valued at about $179,000. Casdin Capital LLC purchased a new position in Magenta Therapeutics in the second quarter valued at about $27,484,000. Millennium Management LLC purchased a new position in Magenta Therapeutics in the second quarter valued at about $1,508,000. Nexthera Capital LP purchased a new position in Magenta Therapeutics in the second quarter valued at about $2,025,000. Finally, Platinum Investment Management Ltd. purchased a new position in Magenta Therapeutics in the second quarter valued at about $675,000. 30.31% of the stock is currently owned by institutional investors.
Shares of MGTA traded up $0.31 during trading hours on Tuesday, hitting $9.88. The stock had a trading volume of 28,800 shares, compared to its average volume of 82,668. Magenta Therapeutics has a 12-month low of $8.59 and a 12-month high of $16.33.
Magenta Therapeutics Company Profile
Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.
See Also: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.